MX2019005330A - Esteroides y conjugados de proteinas de los mismos. - Google Patents

Esteroides y conjugados de proteinas de los mismos.

Info

Publication number
MX2019005330A
MX2019005330A MX2019005330A MX2019005330A MX2019005330A MX 2019005330 A MX2019005330 A MX 2019005330A MX 2019005330 A MX2019005330 A MX 2019005330A MX 2019005330 A MX2019005330 A MX 2019005330A MX 2019005330 A MX2019005330 A MX 2019005330A
Authority
MX
Mexico
Prior art keywords
protein
conjugates
steroids
gcs
glucocorticoids
Prior art date
Application number
MX2019005330A
Other languages
English (en)
Inventor
han Amy
Olson William
Andrew Murphy J
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60409441&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019005330(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2019005330A publication Critical patent/MX2019005330A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0088—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing unsubstituted amino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/0026—Oxygen-containing hetero ring cyclic ketals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/0026—Oxygen-containing hetero ring cyclic ketals
    • C07J71/0031—Oxygen-containing hetero ring cyclic ketals at positions 16, 17

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se describen aquí conjugados de esteroide de proteína que son útiles, por ejemplo, para la entrega específica a objetivo de glucocorticoides (GCs) a las células.
MX2019005330A 2016-11-08 2017-11-07 Esteroides y conjugados de proteinas de los mismos. MX2019005330A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662419365P 2016-11-08 2016-11-08
US201762508317P 2017-05-18 2017-05-18
PCT/US2017/060434 WO2018089373A2 (en) 2016-11-08 2017-11-07 Steroids and protein-conjugates thereof

Publications (1)

Publication Number Publication Date
MX2019005330A true MX2019005330A (es) 2019-09-11

Family

ID=60409441

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019005330A MX2019005330A (es) 2016-11-08 2017-11-07 Esteroides y conjugados de proteinas de los mismos.
MX2021012927A MX2021012927A (es) 2016-11-08 2019-05-07 Esteroides y conjugados de proteinas de los mismos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021012927A MX2021012927A (es) 2016-11-08 2019-05-07 Esteroides y conjugados de proteinas de los mismos.

Country Status (16)

Country Link
US (4) US10711032B2 (es)
EP (1) EP3538539A2 (es)
JP (2) JP7330101B2 (es)
KR (2) KR20240025695A (es)
CN (2) CN110291097A (es)
AU (1) AU2017359043B2 (es)
BR (1) BR112019009019A2 (es)
CA (1) CA3042428A1 (es)
CL (1) CL2019001259A1 (es)
CO (1) CO2019005966A2 (es)
IL (2) IL266353B2 (es)
MX (2) MX2019005330A (es)
PH (1) PH12019501021A1 (es)
SG (1) SG10202104259RA (es)
WO (1) WO2018089373A2 (es)
ZA (1) ZA201902871B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220119529A (ko) 2016-06-02 2022-08-29 애브비 인코포레이티드 글루코코르티코이드 수용체 작용제 및 이의 면역접합체
US10711032B2 (en) 2016-11-08 2020-07-14 Regeneron Pharmaceuticals, Inc. Steroids and protein-conjugates thereof
AU2018270784B2 (en) 2017-05-18 2024-05-16 Regeneron Pharmaceuticals, Inc. Cyclodextrin protein drug conjugates
CA3080857A1 (en) * 2017-11-07 2019-05-16 Regeneron Pharmaceuticals, Inc. Hydrophilic linkers for antibody drug conjugates
WO2019106609A1 (en) 2017-12-01 2019-06-06 Abbvie Inc. Glucocorticoid receptor agonist and immunoconjugates thereof
SG11202006510XA (en) 2018-01-08 2020-08-28 Regeneron Pharma Steroids and antibody-conjugates thereof
KR20210008008A (ko) 2018-05-09 2021-01-20 리제너론 파마슈티칼스 인코포레이티드 항-msr1 항체 및 이의 사용 방법
EA202191430A1 (ru) * 2018-11-20 2021-11-29 Регенерон Фармасьютикалз, Инк. Производные бис-октагидрофенантренкарбоксамида и их белковые конъюгаты
TW202120500A (zh) 2019-08-02 2021-06-01 美商梅爾莎納醫療公司 干擾素基因刺激蛋白（ｓｔｉｎｇ）激動劑化合物及用途
IL295312A (en) 2020-02-28 2022-10-01 Regeneron Pharma Bispecific antigen binding molecules that bind her2 and methods of using them
WO2022015656A1 (en) 2020-07-13 2022-01-20 Regeneron Pharmaceuticals, Inc. Camptothecin analogs conjugated to a glutamine residue in a protein, and their use
CA3190569A1 (en) 2020-10-22 2022-04-28 Christopher Daly Anti-fgfr2 antibodies and methods of use thereof
KR20230107261A (ko) 2020-11-10 2023-07-14 리제너론 파마슈티칼스 인코포레이티드 셀레늄 항체 접합물
CA3200768A1 (en) * 2020-12-04 2022-06-09 Scott Hilderbrand Antibody-oligonucleotide complexes and uses thereof
WO2022135332A1 (zh) * 2020-12-21 2022-06-30 映恩生物制药（苏州）有限公司 一种甾体偶联物
WO2022166779A1 (zh) * 2021-02-04 2022-08-11 上海森辉医药有限公司 糖皮质激素受体激动剂的药物偶联物及其在医药上的应用
WO2022171101A1 (zh) * 2021-02-10 2022-08-18 映恩生物制药（苏州）有限公司 一种甾体偶联物
TW202304462A (zh) 2021-03-23 2023-02-01 美商美國禮來大藥廠 糖皮質素受體激動劑
TW202304464A (zh) 2021-03-23 2023-02-01 美商美國禮來大藥廠 新穎糖皮質素受體激動劑
AR125079A1 (es) 2021-03-23 2023-06-07 Lilly Co Eli Agonistas de receptores de glucocorticoides sustituidos con carboxi
CN113264983A (zh) * 2021-05-20 2021-08-17 联宁（苏州）生物制药有限公司 一种用于抗体偶联药物的连接子lnd1088的合成方法
CN117500816A (zh) * 2021-08-26 2024-02-02 映恩生物制药（苏州）有限公司 一种甾体化合物及其缀合物
CN114394933B (zh) * 2022-01-07 2023-08-22 厦门沃克沃德医药科技有限公司 11,12-二氢-γ-氧代-二苯并[f]偶氮-5-(6h)-丁酸的合成方法
US20230287138A1 (en) 2022-01-12 2023-09-14 Regneron Pharmaceuticals, Inc. Protein-drug conjugates comprising camptothecin analogs and methods of use thereof
US20240067640A1 (en) 2022-03-11 2024-02-29 Firefly Bio, Inc. Phenyl maleimide linker agents
US20240082414A1 (en) 2022-05-13 2024-03-14 Eli Lilly And Company Human tumor necrosis factor alpha antibody glucocorticoid conjugates
TW202400266A (zh) * 2022-05-18 2024-01-01 大陸商成都百利多特生物藥業有限責任公司 配體藥物偶聯物及其應用
JP2024526428A (ja) 2022-06-02 2024-07-18 イーライ リリー アンド カンパニー ヒトインターロイキン－４受容体アルファ抗体グルココルチコイドコンジュゲート
WO2023250341A2 (en) 2022-06-22 2023-12-28 Eli Lilly And Company Human cd33 antibodies and glucocorticoid conjugates
US20240218011A1 (en) 2022-07-21 2024-07-04 Firefly Bio, Inc. Glucocorticoid receptor agonists and conjugates thereof
WO2024064779A1 (en) 2022-09-22 2024-03-28 Eli Lilly And Company Glucocorticoid receptor agonists
US20240269308A1 (en) 2022-12-21 2024-08-15 Regeneron Pharmaceuticals, Inc. Prodrugs of topoisomerase i inhibitor for adc conjugations and methods of use thereof
WO2024140838A1 (zh) * 2022-12-28 2024-07-04 映恩生物制药（苏州）有限公司 抗bdca2抗体-药物偶联物及其用途
WO2024153162A1 (en) * 2023-01-18 2024-07-25 Shanghai Micurx Pharmaceutical Co., Ltd. Peptide-drug conjugates for targeted therapy of renal diseases

Family Cites Families (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2737518A (en) * 1955-01-19 1956-03-06 Schering Corp 1-hydroxycortisone, 1-hydroxyhydrocortisone and esters thereof
US2968655A (en) * 1956-11-23 1961-01-17 Upjohn Co 11-oxygenated-6-methyl progesterone and intermediates therefor
US2920999A (en) 1957-06-07 1960-01-12 Pfizer & Co C 21-nitrogen derivatives of corticosteroids
DE1165595B (de) 1958-03-04 1964-03-19 Olin Mathieson Verfahren zur Herstellung von Triamcinolonacetonid-21-hemisuccinat und dessen Salzen
GB889766A (en) 1958-03-04 1962-02-21 Olin Mathieson Improvements in steroids and the synthesis thereof
US3197469A (en) 1958-08-06 1965-07-27 Pharmaceutical Res Products In 16, 17-acetals and ketals of 6-halo-16, 17-dihydroxy steroids of the pregnane seriesand intermediates therefor
US3007923A (en) * 1959-01-22 1961-11-07 Lab Francais Chimiotherapie Process for the fluorination of 9beta, 11beta-epoxy and 5alpha, 6alpha-epoxy steroids
GB898295A (en) 1959-03-18 1962-06-06 Upjohn Co Improvements in or relating to steroids and the manufacture thereof
US3033873A (en) 1960-05-11 1962-05-08 Pfizer & Co C 21-aminomethyl-pregnenes
US3033874A (en) 1960-05-11 1962-05-08 Pfizer & Co C 17beta-propenoyl steroids and process for preparing same
US3020275A (en) 1960-06-07 1962-02-06 American Cyanamid Co 21-nitrogen substituted steroids of the pregnane series and methods of preparing the same
DE1169444B (de) * 1961-02-22 1964-05-06 Schering Ag Verfahren zur Herstellung von ?-16ª‡-Methylsteroiden
US3047468A (en) * 1961-06-06 1962-07-31 American Cyanamid Co Method of preparing delta1, 4-3-keto steroids of the pregnane series
US3383394A (en) * 1965-08-30 1968-05-14 Schering Corp Novel 17-acylating process and products thereof
US3798216A (en) 1969-03-07 1974-03-19 Fabrication Des Antibiotique S 9-fluoro-11beta,21-dihydroxy-16alpha,17-(2-propenylidenedioxy)-pregna-1,4-diene-3,20-dione and derivatives thereof
DE2047105C3 (de) 1970-09-18 1979-02-15 Schering Ag, 1000 Berlin Und 4619 Bergkamen 17-Chlorsteroide und Verfahren zu ihrer Herstellung
IT1057859B (it) 1972-04-28 1982-03-30 Sigma Tao Ind Farmaceutiche Sp Perivato del triamoinolone
SE378109B (es) 1972-05-19 1975-08-18 Bofors Ab
SE378110B (es) 1972-05-19 1975-08-18 Bofors Ab
US4076737A (en) 1975-02-20 1978-02-28 Ciba-Geigy Corporation Aldehydes of the pregnane series and derivatives thereof
IL73337A (en) 1984-10-28 1988-09-30 Yissum Res Dev Co Antitumor steroid-platinum complexes and method for the preparation thereof
ES8605537A1 (es) 1985-07-03 1986-02-01 Elmu Sa Procedimiento de obtencion de cetales ciclicos de corticoi- des y sus 21-c esteres
SE8604059D0 (sv) 1986-09-25 1986-09-25 Astra Pharma Prod A method of controlling the epimeric distribution in the preparation of 16,17-acetals of pregnane derivatives
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5116829A (en) 1990-04-23 1992-05-26 Kao Corporation Steroid compounds
US5183815A (en) 1991-01-22 1993-02-02 Merck & Co., Inc. Bone acting agents
WO1992022653A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
BR9307746A (pt) 1993-01-08 1995-11-14 Astra Ab Derivados de esteróides especificos para otratamento de cólon e ileo
DE4311987A1 (de) 1993-04-07 1994-10-13 Schering Ag Neue Glucocorticoide
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5824669A (en) 1996-03-22 1998-10-20 Nitromed, Inc. Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
US5837698A (en) 1996-05-02 1998-11-17 G. D. Searle & Co. Steroid nitrite and nitrate ester derivatives useful as anti-inflammatory drugs
WO2000049993A2 (en) 1999-02-24 2000-08-31 Nitromed, Inc. Nitrosated and nitrosylated steroids for the treatment of cardiovascular diseases and disorders
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20070258987A1 (en) 2000-11-28 2007-11-08 Seattle Genetics, Inc. Recombinant Anti-Cd30 Antibodies and Uses Thereof
SE0101220D0 (sv) 2001-04-04 2001-04-04 Astrazeneca Ab New use
US6908934B2 (en) 2001-06-11 2005-06-21 Merck & Co., Inc. Therapeutic compounds for treating dyslipidemic conditions
ITMI20020148A1 (it) 2002-01-29 2003-07-29 Nicox Sa Nuovi corticosteroidi
US20050009798A1 (en) 2002-02-20 2005-01-13 Sepracor Inc. Carbonate and carbamate modified forms of glucocorticoids in combination with B2 adrenergic agonists
US7190468B2 (en) 2002-07-17 2007-03-13 Hewlett-Packard Development Company, L.P. Background document rendering system and method
US7659241B2 (en) 2002-07-31 2010-02-09 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US20040157810A1 (en) 2002-08-23 2004-08-12 Teicher Martin H. Corticosteroid conjugates and uses thereof
CN102516417B (zh) 2002-09-06 2014-12-10 天蓝制药公司 用于传递治疗剂的以环糊精为基础的聚合物
CN1414008A (zh) 2002-10-17 2003-04-30 南开大学 含氮甾体化合物及其制备方法
US7015349B2 (en) 2003-03-26 2006-03-21 The Gillette Company Reduction of hair growth
BR122018071808B8 (pt) 2003-11-06 2020-06-30 Seattle Genetics Inc conjugado
WO2005063777A1 (en) 2003-12-23 2005-07-14 Corus Pharma Benzylphosphate and substituted benzylphosphate prodrugs for the treatment of pulmonary inflammation
US20050192257A1 (en) 2004-02-26 2005-09-01 Peyman Gholam A. Predictors for patients at risk for glaucoma from steroid therapy
TW200539855A (en) 2004-03-15 2005-12-16 Wyeth Corp Calicheamicin conjugates
BRPI0510883B8 (pt) 2004-06-01 2021-05-25 Genentech Inc composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação
EP1602931A1 (en) 2004-06-03 2005-12-07 Universiteit Leiden SR-A antagonists
US7541330B2 (en) 2004-06-15 2009-06-02 Kosan Biosciences Incorporated Conjugates with reduced adverse systemic effects
EP1625854B1 (en) 2004-08-09 2008-10-15 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Albumin conjugates containing a glucuronic linker
TW200616604A (en) 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
CA2587589A1 (en) 2004-11-29 2006-06-22 Seattle Genetics, Inc. Engineered antibodies and immunoconjugates
WO2006135371A1 (en) 2005-06-09 2006-12-21 Kosan Biosciences Incorporated Conjugates with reduced adverse systemic effects
AU2006259604A1 (en) 2005-06-14 2006-12-28 Gilead Sciences, Inc. Substituted phenylphosphates as mutual prodrugs of steroids and beta -agonists for the treatment of pulmonary inflammation and bronchoconstriction
WO2007056181A2 (en) 2005-11-02 2007-05-18 Sicor, Inc. Process for the preparation of ciclesonide
ES2400965T3 (es) 2005-12-22 2013-04-15 Baxter International Inc. Ensayo mejorado de activación de monicitos con mayor capacidad para detectar contaminantes pirotécnicos no endotoxínicos en productos médicos
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
CA2677442A1 (en) 2007-02-05 2008-08-14 Nicox S.A. Nitric oxide releasing steroids
WO2008122039A2 (en) 2007-04-02 2008-10-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selenocysteine mediated hybrid antibody molecules
EP3561513A1 (en) 2007-05-23 2019-10-30 Ventana Medical Systems, Inc. Polymeric carriers for immunohistochemistry and in situ hybridization
CN101784565B (zh) 2007-06-25 2014-12-10 恩多塞特公司 含有亲水性间隔区接头的共轭物
WO2009001364A2 (en) 2007-06-28 2008-12-31 Capsutech Ltd Targeting conjugates comprising active agents encapsulated in cyclodextrin-containing polymers
CN101397328A (zh) 2007-09-27 2009-04-01 天津药业研究院有限公司 一氧化氮供体型糖皮质激素
DK2214646T3 (da) 2007-10-05 2021-10-04 Univ Wayne State Dendrimers for sustained release of compounds
MX2010007023A (es) * 2007-12-21 2010-09-30 Schering Corp Agonistas del receptor glucocorticoide sustituido de c20-c21.
WO2009085880A2 (en) * 2007-12-21 2009-07-09 Schering Corporation C-21 thioethers as glucocorticoid receptor agonists
EP2276506A4 (en) 2008-04-30 2014-05-07 Immunogen Inc EFFICIENT CONJUGATES AND HYDROPHILIC BINDER
EP2294077A1 (en) 2008-06-10 2011-03-16 Gilead Sciences, Inc. Corticosteroid linked beta-agonist compounds for use in therapy
AU2009275358C1 (en) 2008-07-21 2015-09-24 Polytherics Limited Novel reagents and method for conjugating biological molecules
AU2009273251B2 (en) 2008-07-22 2014-12-18 Ablynx Nv Amino acid sequences directed against multitarget scavenger receptors and polypeptides
CA2754589C (en) 2009-03-09 2013-07-16 Mikasa Seiyaku Co., Ltd. Steroid compound
WO2010126953A1 (en) 2009-04-29 2010-11-04 Gilead Sciences, Inc. Corticosteroid linked beta-agonist compounds for use in therapy
WO2010132743A1 (en) 2009-05-15 2010-11-18 Gilead Sciences, Inc. Corticosteroid beta-agonist compounds for use in therapy
DK2889624T3 (en) 2009-08-10 2018-12-10 Ucl Business Plc Reversible covalent bonding of functional molecules
WO2011020107A2 (en) 2009-08-14 2011-02-17 Georgetown University Compositions and methods for detection and treatment of breast cancer
GB0917044D0 (en) 2009-09-29 2009-11-18 Cytoguide As Agents, uses and methods
GB0917054D0 (en) * 2009-09-29 2009-11-11 Cytoguide As Agents, uses and methods
WO2011081937A1 (en) 2009-12-15 2011-07-07 Gilead Sciences, Inc. Corticosteroid-beta-agonist-muscarinic antagonist compounds for use in therapy
WO2011090940A1 (en) 2010-01-19 2011-07-28 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
US9375473B2 (en) 2010-02-19 2016-06-28 Cornell Research Foundation, Inc. Method to treat autoimmune demyelinating diseases and other autoimmune or inflammatory diseases
PE20130342A1 (es) 2010-04-15 2013-04-20 Spirogen Sarl Pirrolobenzodiacepinas y conjugados de las mismas
WO2012005982A2 (en) 2010-07-06 2012-01-12 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Reporter for rna polymerase ii termination
NZ606824A (en) 2010-08-02 2015-05-29 Regeneron Pharma Mice that make binding proteins comprising vl domains
UA109150C2 (xx) 2010-09-01 2015-07-27 Аміди n-(тетразол-5-іл)- або n-(триазол-5-іл)арилкарбонової кислоти та їх застосування як гербіцидів
AU2011320318B9 (en) 2010-10-29 2015-11-19 Immunogen, Inc. Non-antagonistic EGFR-binding molecules and immunoconjugates thereof
US20120302505A1 (en) 2011-04-21 2012-11-29 Fetzer Oliver S Cyclodextrin-based polymers for therapeutic delivery
MX345538B (es) 2011-05-27 2017-02-03 Ambrx Inc Composiciones que contienen, metodos que incluyen, y usos de derivados de dolastatina enlazados a aminoacidos no naturales.
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
US9526798B2 (en) 2011-10-14 2016-12-27 Seattle Genetics, Inc. Pyrrolobenzodiazepines and targeted conjugates
US9399073B2 (en) 2011-10-14 2016-07-26 Seattle Genetics, Inc. Pyrrolobenzodiazepines
CN104011018B (zh) 2011-10-14 2016-12-14 麦迪穆有限责任公司 可用于制备吡咯并苯并二氮杂卓的合成方法和中间体
BR112014009055B1 (pt) 2011-10-14 2021-12-14 Seattle Genetics, Inc. Compostos pirrolobenzodiazepinas, conjugados alvos, ligante de fármaco e uso dos ditos conjugados para tratar uma doença proliferativa
WO2013068874A1 (en) 2011-11-11 2013-05-16 Pfizer Inc. Antibody-drug conjugates
MX2014006739A (es) 2011-12-05 2015-06-05 Igenica Biotherapeutics Inc Conjugados de anticuerpo-farmaco y compuestos relacionados, composiciones , y metodos.
GB201122325D0 (en) 2011-12-23 2012-02-01 Cytoguide As Novel formulations
AU2013274078A1 (en) 2012-06-14 2015-01-29 Ambrx, Inc. Anti-PSMA antibodies conjugated to nuclear receptor ligand polypeptides
CA2885169C (en) 2012-10-11 2021-06-22 Ascendis Pharma A/S Diagnosis, prevention and treatment of diseases of the joint
AU2013331440A1 (en) 2012-10-16 2015-04-30 Endocyte, Inc. Drug delivery conjugates containing unnatural amino acids and methods for using
SI2911699T1 (en) 2012-10-23 2018-04-30 Synaffix B.V. MODIFIED AGAINST, PROTITELO-KONJUGAT AND PROCESS FOR THEIR PREPARATION
WO2014065575A1 (ko) 2012-10-25 2014-05-01 주식회사유한양행 4,5-다이하이드로-1h-피라졸 유도체 또는 그의 염 및 이를 포함하는 약학 조성물
PT2935331T (pt) 2012-12-24 2018-06-04 Abbvie Inc Proteínas de ligação ao recetor de prolactina e suas utilizações
CN105189546B (zh) 2013-03-13 2022-09-02 西雅图基因公司 环糊精和抗体-药物偶联物制剂
US20160082119A1 (en) 2013-04-22 2016-03-24 Avelas Biosciences, Inc. Selective drug delivery compositions and methods of use
WO2014197854A1 (en) 2013-06-06 2014-12-11 Igenica Biotherapeutics, Inc. Novel linkers for antibody-drug conjugates and related compounds, compositions, and methods of use
CA2914189C (en) 2013-06-21 2023-03-14 Innate Pharma Enzymatic conjugation of polypeptides
EP3020417A4 (en) 2013-07-10 2017-01-18 Seikagaku Corporation Pharmaceutical composition for respiratory administration
TWI641620B (zh) 2013-08-21 2018-11-21 再生元醫藥公司 抗－ｐｒｌｒ抗體及其用途
EA201690780A1 (ru) 2013-10-15 2016-08-31 Сиэтл Дженетикс, Инк. Пегилированные лекарственные средства-линкеры для улучшенной фармакокинетики конъюгатов лиганд-лекарственное средство
GB201320091D0 (en) 2013-11-14 2014-01-01 Univ Manchester Selective glucocorticoid receptor ligands
CN103694375B (zh) 2013-12-13 2016-10-05 北京大学 一种三萜-环糊精共价化合物及其制备方法和用途
US10485811B2 (en) 2014-01-24 2019-11-26 Centre National De La Recherche Scientifique Orally available compounds, a process for preparing the same and their uses as anti-adhesive drugs for treating E. coli induced inflammatory bowel diseases such as crohn's disease
EP3125943A4 (en) 2014-04-04 2017-12-06 Merck Sharp & Dohme Corp. Phosphate based linkers for intracellular delivery of drug conjugates
WO2015155998A1 (en) 2014-04-10 2015-10-15 Daiichi Sankyo Company, Limited Anti-her3 antibody-drug conjugate
US20170189549A1 (en) 2014-06-13 2017-07-06 Glykos Finland Oy Payload-Polymer-Protein Conjugates
CN107206102A (zh) 2014-12-03 2017-09-26 豪夫迈·罗氏有限公司 抗金黄色葡萄球菌抗体利福霉素缀合物及其用途
CN107249642A (zh) 2014-12-03 2017-10-13 豪夫迈·罗氏有限公司 抗金黄色葡萄球菌抗体利福霉素缀合物及其用途
WO2016094517A1 (en) 2014-12-09 2016-06-16 Abbvie Inc. Bcl-xl inhibitory compounds and antibody drug conjugates including the same
CN111620861A (zh) 2014-12-09 2020-09-04 艾伯维公司 具有低细胞渗透性的bcl-xl抑制性化合物以及包括它的抗体药物缀合物
EP3250211B1 (en) 2015-01-30 2021-12-22 Coral Drugs Pvt. Ltd. Novel process for preparation of glucocorticoid steroids
EP3253212A4 (en) 2015-02-06 2018-09-19 Sorrento Therapeutics, Inc. Antibody drug conjugates
WO2017006279A1 (en) 2015-07-08 2017-01-12 Aten Porus Lifesciences Cyclodextrin-polymer complexes and compostions and methods of making and using the same
WO2017044983A1 (en) 2015-09-10 2017-03-16 Shasqi, Inc. Bioorthogonal compositions
US11510993B2 (en) 2015-10-06 2022-11-29 Merck Sharp & Dohme Llc Antibody drug conjugate for anti-inflammatory applications
EP3407916B1 (en) 2016-01-29 2023-12-20 Merck Sharp & Dohme LLC Phosphonate linkers and their use to facilitate cellular retention of compounds
US11786603B2 (en) 2016-02-26 2023-10-17 Regeneron Pharmaceuticals, Inc. Optimized transglutaminase site-specific antibody conjugation
EA201892040A1 (ru) 2016-03-25 2019-04-30 Сиэтл Дженетикс, Инк. Способ получения пегилированных соединений лекарственный препарат - линкер и их промежуточных соединений
GB201608936D0 (en) 2016-05-20 2016-07-06 Polytherics Ltd Novel conjugates and novel conjugating reagents
KR20220119529A (ko) 2016-06-02 2022-08-29 애브비 인코포레이티드 글루코코르티코이드 수용체 작용제 및 이의 면역접합체
JP2019522643A (ja) 2016-06-08 2019-08-15 アッヴィ・インコーポレイテッド 抗ｃｄ９８抗体及び抗体薬物コンジュゲート
CA3037732A1 (en) 2016-09-23 2018-03-29 Regeneron Pharmaceuticals, Inc. Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof
US10711032B2 (en) 2016-11-08 2020-07-14 Regeneron Pharmaceuticals, Inc. Steroids and protein-conjugates thereof
KR20240110082A (ko) 2017-02-28 2024-07-12 이뮤노젠 아이엔씨 자기희생적 펩티드 링커 및 이들의 접합체를 갖는 메이탄시노이드 유도체
AU2018270784B2 (en) 2017-05-18 2024-05-16 Regeneron Pharmaceuticals, Inc. Cyclodextrin protein drug conjugates
MA47392B1 (fr) 2017-05-18 2021-09-30 Regeneron Pharma Bis-octahydrophénanthrène carboxamides et leurs conjugués protéiques
EP3630189A4 (en) 2017-05-24 2021-06-23 The Board of Regents of The University of Texas System LINKER FOR ANTIBODY MEDICINAL CONJUGATES
CN109106951A (zh) 2017-08-18 2019-01-01 四川百利药业有限责任公司 一种喜树碱-抗体偶联物
WO2019034177A1 (zh) 2017-08-18 2019-02-21 四川百利药业有限责任公司 具有两种不同药物的抗体药物偶联物
CA3080857A1 (en) 2017-11-07 2019-05-16 Regeneron Pharmaceuticals, Inc. Hydrophilic linkers for antibody drug conjugates
SG11202006510XA (en) 2018-01-08 2020-08-28 Regeneron Pharma Steroids and antibody-conjugates thereof
JP7430643B2 (ja) 2018-04-06 2024-02-13 シージェン インコーポレイテッド カンプトテシンペプチドコンジュゲート
KR20210008008A (ko) 2018-05-09 2021-01-20 리제너론 파마슈티칼스 인코포레이티드 항-msr1 항체 및 이의 사용 방법
WO2020132483A1 (en) 2018-12-21 2020-06-25 Regeneron Pharmaceuticals, Inc. Rifamycin analogs and antibody-drug conjugates thereof
SG11202107212QA (en) 2019-01-08 2021-07-29 Regeneron Pharma Traceless linkers and protein-conjugates thereof

Also Published As

Publication number Publication date
US11760775B2 (en) 2023-09-19
JP7330101B2 (ja) 2023-08-21
MX2021012927A (es) 2022-01-31
WO2018089373A9 (en) 2018-07-12
US20240101594A1 (en) 2024-03-28
IL266353B1 (en) 2023-11-01
CL2019001259A1 (es) 2019-07-19
IL266353A (en) 2019-06-30
CN115651056A (zh) 2023-01-31
AU2017359043A1 (en) 2019-05-23
US20210332080A1 (en) 2021-10-28
US10711032B2 (en) 2020-07-14
IL307357A (en) 2023-11-01
SG10202104259RA (en) 2021-06-29
WO2018089373A3 (en) 2018-06-21
ZA201902871B (en) 2023-12-20
PH12019501021A1 (en) 2019-06-24
JP2023153988A (ja) 2023-10-18
CO2019005966A2 (es) 2019-07-10
JP2019536765A (ja) 2019-12-19
CA3042428A1 (en) 2018-05-17
CN110291097A (zh) 2019-09-27
US20210040144A1 (en) 2021-02-11
KR20190074310A (ko) 2019-06-27
EP3538539A2 (en) 2019-09-18
AU2017359043B2 (en) 2022-06-16
WO2018089373A2 (en) 2018-05-17
US20180155389A1 (en) 2018-06-07
KR20240025695A (ko) 2024-02-27
IL266353B2 (en) 2024-03-01
BR112019009019A2 (pt) 2019-07-09

Similar Documents

Publication Publication Date Title
PH12019501021A1 (en) Steroids and protein-conjugates thereof
PH12020551044A1 (en) Steroids and antibody-conjugates thereof
PH12017502390A1 (en) Constructs targeting ny-eso-1 peptide/mhc complexes and uses thereof
MX2018011706A (es) Composicion farmaceutica de hormona esteroide.
BR112018014760A2 (pt) anticorpos anti-ror1, anticorpos biespecíficos para ror1 x cd3 e métodos de uso dos mesmos
MX2018015272A (es) Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
MY186708A (en) Constructs targeting afp peptide/mhc complexes and uses thereof
EP3426257A4 (en) NEUROACTIVE STEROIDS, COMPOSITIONS AND USES THEREOF
MX2018003689A (es) Proteinas de union a pd-1 y metodos para usarlas.
MX2017014056A (es) Construcciones dirigidas a complejos de peptido e7 del subtipo 16 del virus de papiloma humano (hpv16-e7)/complejo principal de histocompatibilidad (mhc) y sus usos.
MX360666B (es) Composiciones de yodopovidona estables con antiinflamatorios esteroides y no esteroides.
MA40459A (fr) Anticorps anti-age pour le traitement de l'inflammation et de troubles auto-immuns
MX2018015274A (es) Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
ZA201807920B (en) Anti¿gitr antibodies and uses thereof
WO2020051333A8 (en) Anti-avb8 antibodies and compositions and uses thereof
BR112018075651A2 (pt) anticorpos anti-cd98 e conjugados anticorpo fármaco
WO2018119425A3 (en) Anti-lilrb3 antibodies and methods of use thereof
EP3462875A4 (en) COMPOSITIONS AND METHODS WITH THE ANDERSTENONE, TESTOSTERONE, PROGESTERONE AND ESTROGEN PHEROMONIC COMPOUNDS
PH12018500159A1 (en) Constructs targeting psa peptide/mhc complexes and uses thereof
MX2018010491A (es) Proceso para la preparacion de un conjugado anticuerpo-rifamicina.
JOP20210014A1 (ar) تركيبات مضادات fcrn وطرق استخدامها
WO2018175740A8 (en) Anti-tmeff1 antibodies and antibody drug conjugates
CY1125282T1 (el) Υδροξυλιωση στη θεση 21 των στεροειδων
MX2019005933A (es) Polipeptidos biespecificos para gitr y ctla-4.
EP3886921A4 (en) ACTINIUM 225 AND ACTINIUM 227 CONJUGATED ANTIBODIES, COMPOSITIONS AND METHODS RELATED